Enthera Pharmaceuticals was co-founded by faculty from University of Milan and is using stem cells to treat autoimmune disorders.

Enthera Pharmaceuticals, an Italy-based biotechnology developer focused on autoimmune conditions, today collected €28m ($32.8m) in a series A round co-led by pharmaceutical firm AbbVie’s corporate venturing arm AbbVie Ventures. VC firm Sofinnova Partners co-led the round, which also included unnamed individuals coordinated by wealth management firm Banor SIM and by asset management firm Banca Profilo…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.